Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Integra Lifesciences Holdings (IART) EBT (2016 - 2026)

Integra Lifesciences Holdings' EBT history spans 17 years, with the latest figure at $4.3 million for Q4 2025.

  • On a quarterly basis, EBT fell 80.88% to $4.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$563.5 million, a 2990.05% decrease, with the full-year FY2025 number at -$563.5 million, down 2989.88% from a year prior.
  • EBT hit $4.3 million in Q4 2025 for Integra Lifesciences Holdings, up from -$6.8 million in the prior quarter.
  • Over the last five years, EBT for IART hit a ceiling of $67.3 million in Q1 2021 and a floor of -$531.0 million in Q2 2025.
  • Historically, EBT has averaged -$3.6 million across 5 years, with a median of $25.7 million in 2023.
  • Biggest five-year swings in EBT: skyrocketed 2614.96% in 2021 and later plummeted 3396.56% in 2025.
  • Tracing IART's EBT over 5 years: stood at $51.8 million in 2021, then rose by 23.98% to $64.2 million in 2022, then tumbled by 55.06% to $28.9 million in 2023, then dropped by 21.89% to $22.5 million in 2024, then crashed by 80.88% to $4.3 million in 2025.
  • Business Quant data shows EBT for IART at $4.3 million in Q4 2025, -$6.8 million in Q3 2025, and -$531.0 million in Q2 2025.